Syntax Research Inc. Sells 2,879 Shares of Elevance Health, Inc. $ELV

Syntax Research Inc. cut its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 96.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 121 shares of the company’s stock after selling 2,879 shares during the quarter. Syntax Research Inc.’s holdings in Elevance Health were worth $39,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ELV. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Elevance Health by 5.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,009 shares of the company’s stock worth $15,562,000 after acquiring an additional 2,154 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in Elevance Health by 2.5% during the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 1,820 shares of the company’s stock worth $708,000 after acquiring an additional 44 shares during the last quarter. Checchi Capital Advisers LLC raised its position in Elevance Health by 7.1% during the 2nd quarter. Checchi Capital Advisers LLC now owns 2,931 shares of the company’s stock worth $1,140,000 after purchasing an additional 194 shares during the last quarter. Berger Financial Group Inc lifted its stake in shares of Elevance Health by 1.9% in the second quarter. Berger Financial Group Inc now owns 14,523 shares of the company’s stock worth $5,649,000 after acquiring an additional 275 shares during the period. Finally, Wealthcare Advisory Partners LLC boosted its holdings in Elevance Health by 2.3% in the second quarter. Wealthcare Advisory Partners LLC now owns 3,006 shares of the company’s stock valued at $1,169,000 after acquiring an additional 67 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on ELV. Morgan Stanley lowered their price objective on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. Wall Street Zen raised shares of Elevance Health from a “hold” rating to a “buy” rating in a research report on Saturday. Leerink Partners raised their price objective on Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a research note on Thursday. UBS Group set a $400.00 target price on Elevance Health in a research note on Thursday. Finally, Wolfe Research set a $425.00 price objective on Elevance Health and gave the company an “outperform” rating in a research note on Thursday, January 8th. Thirteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $396.90.

Elevance Health Stock Performance

NYSE:ELV opened at $345.62 on Monday. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. The firm has a market cap of $76.81 billion, a price-to-earnings ratio of 13.76, a PEG ratio of 1.93 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54. The business’s fifty day moving average is $351.69 and its 200 day moving average is $328.87.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is presently 27.23%.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.